Loading data for IMMX — first visit, this takes a few seconds.

알림

Immix Biopharma Inc. (IMMX)

NasdaqCM: IMMX · 실시간 가격 · USD

11.81

+0.47 (4.14%)

종가 기준: Aug 19, 2026, 2:07 PM

4.14% (1D)

데이터 없음

매수호가	8.37
시가총액	907.67M
매출 (ttm)	n/a
순이익 (ttm)	-39.92M
베타	0.11
EPS (ttm)	-0.88
P/E (ttm)	n/a
선행 P/E	-14.11
P/B (ttm)	3.98
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	14.41
거래량	1,327,584
평균 거래량 (20일)	1,890,916
시가	11.36
전일 종가	11.34
일중 범위	11.06 - 11.86
52주 범위	1.94 - 12.14
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IMMX 소개

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 16, 2021

직원 수 21

상장 거래소 NasdaqCM

티커 IMMX

웹사이트 https://www.immixbio.com

전체 기업 정보

재무 실적

2025년 Immix Biopharma의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -29.44M로, 36.21% 증가했습니다.

재무제표

어닝 서프라이즈

Immix Biopharma가 Aug 7, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.18 예상치 하회 0.00, 및 18.18% 전년 대비 성장.

뉴스

4주 전 · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

2개월 전 · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

2개월 전 · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

2개월 전 · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3개월 전 · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

2 페이지 중 1

Immix Biopharma Inc. (IMMX)